A key prerequisite for precision medicine is the ability to assess metrics of human behavior objectively, unobtrusively and continuously. This capability serves as a framework for the optimization of tailored, just-in-time precision health interventions. Mobile unobtrusive physiological sensors, an important prerequisite for realizing this vision, show promise in implementing this quality of physiological data collection. However, first we must trust the collected data. In this paper, we present a novel approach to improving heart rate estimates from wrist pulse photoplethysmography (PPG) sensors. We also discuss the impact of sensor movement on the veracity of collected heart rate data.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994914 | PMC |
| http://dx.doi.org/10.1109/EMBC.2017.8037141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review on whole-body photobiomodulation for exercise performance and recovery.
Lasers Med Sci
January 2025
Cornell University, Ithaca, USA.
Purpose: Photobiomodulation (PBM) is a non-invasive therapeutic procedure that consists of irradiating a local area of the skin with red and near-infrared lasers or light emitting diodes (LEDs). Local PBM has been studied as a method to improve exercise performance and recovery. This review aims to evaluate the efficacy of whole-body PBM for exercise performance and recovery, comparing its findings to the established effects of localized PBM.
View Article and Find Full Text PDFAn Update on Multi-System Inflammatory Syndrome in Children.
Curr Rheumatol Rep
January 2025
Division of Rheumatology, Department of Pediatrics, The Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI, 02903, USA.
Purpose: To summarize the latest research on the epidemiology, pathogenesis, diagnosis, and treatment of multisystem inflammatory syndrome in children (MIS-C).
Recent Findings: The epidemiology of MIS-C has been dynamic since its initial description. The pathogenesis remains poorly understood.
European central hypoventilation syndrome consortium description of congenital central hypoventilation syndrome neonatal onset.
Eur J Pediatr
January 2025
Service de Physiologie Pédiatrique-Centre du Sommeil-CRMR Hypoventilations Alvéolaires Rares, INSERM NeuroDiderot, Université Paris-Cité, AP-HP, Hôpital Robert Debré, Paris, France.
Unlabelled: It is known that in most cases of congenital central hypoventilation syndrome (CCHS), apnoeas and hypoventilation occur at birth. Nevertheless, a detailed description of initial symptoms, including pregnancy events and diagnostic tests performed, is warranted in infants with neonatal onset of CCHS, that is, in the first month of life. The European Central Hypoventilation Syndrome Consortium created an online patient registry from which 97 infants (44 females) with CCHS of neonatal onset and PHOX2B mutation from 10 countries were selected.
View Article and Find Full Text PDFIntermittent Fetal Heart Monitoring Through Moyo Doppler Improves Nonreassuring Fetal Heart Rate Detection in Hospital of Ethiopia: A Randomized Controlled Trial.
J Perinat Neonatal Nurs
January 2025
Author Affiliations: Departments of Midwifery (Mr Fikadu), Internal Medicine (Dr Shibru), and Obstetrics and Gynecology (Drs Koira, Chufamo, and Mulugeta), and School of Public Health (Messrs Kote and Hailemariam and Dr Ayele), College of Medicine and Health Sciences, Arba Minch University, Southern Region, Arba Minch, Ethiopia; Ethiopia Midwives Association, Addis Ababa, Ethiopia (Messrs Belgu and Mazengia); and Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Amhara Region, Gondar, Ethiopia (Dr Ayele).
Purpose: This study was aimed to assess the effect of intermittent fetal heart rate (FHR) monitoring using Moyo Doppler compared with fetoscope in hospitals of Ethiopia, 2023.
Background: To facilitate more prompt identification of a hypoxic fetus, Laerdal Global Health has recently introduced the Moyo FHR monitor. Nevertheless, there exists limited knowledge regarding its efficacy derived from multicenter contextual trials conducted in resource-constrained environments, specifically in Ethiopia.
Background: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been added to the mainstay of treatment for chronic heart failure. Recent studies suggest that empagliflozin may also reverse cardiac remodeling in heart failure by reducing N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. In our study, we wanted to show the decrease in NT-proBNP levels, which is an indicator of poor prognosis in heart failure, and to see if there was a decrease in the rate of renal progression in patients with HF after empagliflozin use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!